维思通治疗首发精神分裂症的临床试验观察

Clinical experiment of risperridone in the treatment on first-episode schizophreania

目的：了解维思通作为治疗首发精神分裂症的临床疗效及副作用。方法：使用维思通治疗精神分裂症患者８７例，用简明精神病量表（ＢＰＲＳ）对用药前后进行评定，对有无家族史，不同病程的疗效进行对比，以治疗时不良反应量表（ＴＥＳＳ）对药物的副作用进行对比。结果：治疗结束时，显效率（显好＋痊愈）为６４．３７％，有效率为９１．９５％。维思通治疗的起效时间为２周。有效治疗日剂量为５．３２１８ｍｇ±１．９４８４ ｍｇ。有无家族史的治疗无显著性意义．病程５ａ内的患者治疗２周疗效与１０ ａ以上的患者有显著性意义，８周后，各病程均无显著性意义。药物的副作用以锥体外系反应较显著。结论：维思通治疗精神分裂症是一种起效快，效果好．副作用少的抗精神病药物．

Objective: The purpose of the study was to investigate the therapeutic efficacy and side effects of risperidone in the treatment of first - episode schizophrenic patients. Methods: 87 patients with schizophrenic was treated by risperidone in 8-week. The brief psychiatric rating scale(BPRS) was used for the efficacy and Treatment Emergent Symptom Scale (TESS) for unwanted effects. These patients were divided into groups according to family history and course of diseases. Results:At the end of study,64. 37% of the patients were rated as marked improvement and 91. 95 % of them as improvement ,the optimal dose ranged from 5. 3218 mg/d±１. 9484 mg/d. The clinical effectiveness showed up at the end of the second week of treatment. No significant difference between the grorp with family history and without family history. Both the group in 5 years and the group beyond 10 years were significantly difference at the end of the second week of treatment. After 8 weeks,non-significant difference among the groups of course of diseases. The common side effects of risperidone were extrapyamidal side effects. Conclusion:Risperidone is one of antipsychotics which is safe and effective.